Korro Bio(KRRO) - 2024 Q2 - Quarterly Results

Exhibit 99.1 KORROS Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates — Regulatory filing of first-in-human (FIH) trial of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) anticipated in the second half of 2024 — Preclinical data presented at the American Thoracic Society International Conference (ATS) demonstrating KRRO-110's ability to correct alpha-1 antitrypsin (AAT) protein resulting in >70% of circulating protein to be M-AAT and concomitantly reducing the ...